This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spiro, S. G. Articles by Hackshaw, A. K. Search for Related Content PubMed PubMed Citation Articles by Spiro, S. G. Articles by Hackshaw, A. K. Social Bookmarking                            What's this?

Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis

Stephen G. Spiro, Lindsay E. James, Robin M. Rudd, Colin W. Trask, Jeffrey S. Tobias, Michael Snee, David Gilligan, Philip A. Murray, Mary Carmen Ruiz de Elvira, Katy M. O'Donnell, Nicole H. Gower, Peter G. Harper, Allan K. Hackshaw

From the University College Hospitals Trust; Cancer Research UK and University College London Cancer Trials Centre; St Bartholomew's Hospital; Guy's and St Thomas' National Health Services (NHS) Trust, London; Southend Hospital NHS Trust, Southend; Cookridge Hospital, Leeds; Addenbrookes NHS Trust, Cambridge; and Essex County Hospital NHS Trust, Essex, United Kingdom

Address reprint requests to Allan K. Hackshaw, MSc, Cancer Research UK and University College London Cancer Trials Centre, Stephenson House, 158-160 N Gower St, London NW1 2ND, United Kingdom; e-mail: ah{at}ctc.ucl.ac.uk

PURPOSE: To replicate an earlier National Cancer Institute of Canada (NCIC) trial that examined the effect on survival of the timing of thoracic radiotherapy (TRT) in patients with limited disease small-cell lung cancer (SCLC).

PATIENTS AND METHODS: Patients received three cycles of cyclophosphamide, doxorubicin, and vincristine alternating with three cycles of etoposide and cisplatin. Three hundred twenty five chemotherapy- and radiotherapy-naïve patients were randomly assigned to either early TRT administered concurrently in the second cycle or late TRT administered concurrently with the sixth cycle; the dose was 40 Gy in 15 fractions over 3 weeks.

RESULTS: TRT was received by 92% and 82% of patients in the early and late arms, respectively (P = .01). Sixty-nine percent of patients in the early arm received all six courses of chemotherapy compared with 80% in the late arm (P = .003). There was no evidence of a survival difference; median overall survival time was 13.7 and 15.1 months in the early and late arms, respectively (P = .23). In a meta-analysis of all eight trials that compared early and late TRT, there were three in which the proportion of patients who completed their planned chemotherapy was similar between the TRT arms (hazard ratio [HR] = 0.73; 95% CI, 0.62 to 0.86) and five in which proportionally fewer patients in the early TRT arm completed their chemotherapy (HR = 1.06; 95% CI, 0.97 to 1.17).

CONCLUSION: This study failed to show a survival advantage for early TRT with chemotherapy in limited-stage SCLC, unlike the NCIC trial. However, the results of a meta-analysis suggest that it is essential to ensure that the delivery of chemotherapy is optimal when administered with early TRT.

Presented in part at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 31-June 3, 2003.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. M. Lee, P. J. Woll, R. Rudd, D. Ferry, M. O'Brien, G. Middleton, S. Spiro, L. James, K. Ali, M. Jitlal, et al. Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial J Natl Cancer Inst, August 5, 2009; 101(15): 1049 - 1057. [Abstract] [Full Text] [PDF]

				M. Sorensen, E. Felip, and On behalf of the ESMO Guidelines Working Group Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Ann. Onc., May 1, 2009; 20(suppl_4): iv71 - iv72. [Full Text] [PDF]

				J. P. Sculier, J. J. Lafitte, A. Efremidis, M. C. Florin, J. Lecomte, M. C. Berchier, M. Richez, T. Berghmans, A. Scherpereel, A. P. Meert, et al. A phase III randomised study of concomitant induction radiochemotherapy testing two modalities of radiosensitisation by cisplatin (standard versus daily) for limited small-cell lung cancer Ann. Onc., October 1, 2008; 19(10): 1691 - 1697. [Abstract] [Full Text] [PDF]

				G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later Postgrad. Med. J., April 1, 2008; 84(990): 182 - 187. [Full Text] [PDF]

				M. A. Socinski and J. A. Bogart Limited-Stage Small-Cell Lung Cancer: The Current Status of Combined-Modality Therapy J. Clin. Oncol., September 10, 2007; 25(26): 4137 - 4145. [Abstract] [Full Text] [PDF]

				G. R. Simon and A. Turrisi Management of Small Cell Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 324S - 339S. [Abstract] [Full Text] [PDF]

				B. E. Lally, J. J. Urbanic, A. W. Blackstock, A. A. Miller, and M. C. Perry Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years? Oncologist, September 1, 2007; 12(9): 1096 - 1104. [Abstract] [Full Text] [PDF]

				G A Silvestri and S G Spiro Carcinoma of the bronchus 60 years later. Thorax, December 1, 2006; 61(12): 1023 - 1028. [Full Text] [PDF]

				M. C. Perry Thoracic Radiation Therapy in Limited Stage Small-Cell Lung Cancer: Timing Is Everything...Isn't It? J. Clin. Oncol., August 20, 2006; 24(24): 3815 - 3816. [Full Text] [PDF]